BCM
ANIX icon

Bridgeway Capital Management’s Anixa Biosciences ANIX Stock Holding History

Bridgeway Capital Management’s Portfolio ANIX Stock Details ANIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-21,000
Closed -$68.7K – 1363
2023
Q3 		$68.7K Hold
21,000
– – ﹤0.01% 1271
2023
Q2 		$67.2K Hold
21,000
– – ﹤0.01% 1308
2023
Q1 		$90.3K Hold
21,000
– – ﹤0.01% 1255
2022
Q4 		$89.3K Buy
+21,000
New +$101K ﹤0.01% 1233

Other funds holding ANIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MWM
Mission Wealth Management Santa Barbara, California $4.86B AUM 22.78% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Bridgeway Capital Management's ANIX Position: Q4 2023 in Review

Bridgeway Capital Management sold out of Anixa Biosciences (ANIX) in Q4 2023, closing a stake of 21,000 shares — an estimated $68.7K sold.

Bridgeway Capital Management first reported a position in ANIX in Q4 2022 and held it in 4 quarters. The position peaked at $90.3K in Q1 2023. 55 funds tracked by Wall St. Rank hold ANIX as of Q4 2023.

  • Bridgeway Capital Management reported no remaining Anixa Biosciences position as of Q4 2023 after selling out during the quarter.
  • Bridgeway Capital Management sold 21,000 Anixa Biosciences shares in Q4 2023, an estimated $68.7K.
  • Bridgeway Capital Management first reported a position in Anixa Biosciences in Q4 2022 and held it in 4 quarters.
  • Bridgeway Capital Management's Anixa Biosciences position peaked at $90.3K in Q1 2023.
  • 55 funds tracked by Wall St. Rank held Anixa Biosciences as of Q4 2023.

Based on Bridgeway Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.